The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit Podcast 226 – Airway Update – Bougie and Positioning - June 13, 2018
- EMCrit Podcast 225 – Tox(&Hound)idromes with Howard & Dan - May 28, 2018
- EMCrit Podcast 224 – TTP & DIC with Tom DeLoughery – Part II – Treatment - May 14, 2018